Parexel International competitors

James Clifford Foster is the chairman and chief executive officer of Charles River Laboratories, Inc., an international company that works on the drug discovery and development process. Charles River Laboratories is the world's largest breeder of animals for use in laboratory experimentation.

August Troendle is a Chairman/President/CEO/Founder at Medpace and is based in Ohio. He has worked as Board Member at Xenon Pharmaceuticals Inc. and Board Member at COHERUS BIOSCIENCES, INC.. August studied at University of Maryland.

Albert Bourla (Greek: Άλμπερτ Μπουρλά, born) is a Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.

Colin Shannon is President, Chief Executive Officer (CEO) and Director for PRA. Since 2007, Mr. Shannon has served as President and Chief Operating Officer (COO) for PRA. Mr. Shannon has contributed significantly to the development of PRA's current mission and vision. As COO, he has been instrumental in driving PRA's decision-making processes and building a talented pool of clinical professionals.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Paul Kirchgraber is a CEO at Covance.

Dr. Rose obtained his B.S.E. in Biomedical Engineering at the University of Michigan in 2006 and his M.D. from Wayne State University School of Medicine in 2010. He went on to Duke University Medical Center in North Carolina for his Internal Medicine Residency and the University of Pittsburgh for Pulmonary & Critical Care Medicine Fellowship. He obtained his MBA from Carnegie Mellon University’s Tepper School of Business in 2017 in a novel Biomedical Entrepreneurship Track. He is currently an Assistant Professor of Medicine at the University of Pittsburgh. He is part of the scientific team that developed Globin Solution’s lead compound, recombinant neuroglobin. His academic research work focuses on understanding the molecular mechanisms of CO poisoning and the effects of carbon monoxide poisoning on patients. He continues to serve as an attending physician in the intensive care unit. Dr Rose cofounded Globin Solutions, Inc., along with Drs. Gladwin and Tejero in 2017.